基于肿瘤临床前模型建立头颈癌新型药物基因组学的必要性及展望
孙树洋， 张志愿 - 山东大学学报(医学版), 2021 - yxbwk.njournal.sdu.edu.cn
… Abstract: Head and neck cancer is the seventh common malignant tumor in the world. For
more than 60% patients, the diagnosis is made at an intermediate or advanced stage. …
more than 60% patients, the diagnosis is made at an intermediate or advanced stage. …
以生物資訊學模式探討腫瘤微環境對頭頸癌病患接受免疫調節點抑制劑複方治療之效應研究
高祥豐 - 2022 - tdr.lib.ntu.edu.tw
… , afatinib augments pembrolizumab therapy and improves the ORR in HNSCC patients by
… HNSCC, adding cetuximab to cisplatin plus fluorouracil improves the objective response …
… HNSCC, adding cetuximab to cisplatin plus fluorouracil improves the objective response …
[HTML][HTML] PD-1/L1 抑制剂在头颈部鳞状细胞癌治疗中的应用进展
攀宋， 晓晴颜， 燕慧姜， 煜初叶， 静怡王… - … , Head, and Neck …, 2022 - ncbi.nlm.nih.gov
… KEYNOTE-012试验证实了帕博利珠单抗(pembrolizumab)单药治疗在PD-L1阳性R/M HNSCC患者
中的抗肿瘤活性，ORR为18%。其扩展队列在降低给药频率后，尽管未考虑肿瘤细胞PD-L1…
中的抗肿瘤活性，ORR为18%。其扩展队列在降低给药频率后，尽管未考虑肿瘤细胞PD-L1…
复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识(2024 年版)
郭晔， 张陈平 - 中国癌症杂志, 2024 - china-oncology.com
… For patients who are intolerant of chemotherapy and … , pembrolizumab or nivolumab in
combination with cetuximab can … Platinumbased chemotherapy plus cetuximab in head and neck …
combination with cetuximab can … Platinumbased chemotherapy plus cetuximab in head and neck …
局部晚期头颈部鳞状细胞癌的化疗及靶向进展
卫亚楠， 陈曦 - 山东大学耳鼻喉眼学报, 2021 - ebhyxbwk.njournal.sdu.edu.cn
… for locally advanced head and neck squamous cell carcinoma(… In 2006, cetuximab(CET)was
approved by the US Food and … locally advanced head and neck squamous cell carcinoma. …
approved by the US Food and … locally advanced head and neck squamous cell carcinoma. …
头颈鳞状细胞癌新辅助免疫治疗进展
王朝阳， 桂琳， 何小慧， 安常明 - 国际耳鼻咽喉头颈外科杂志, 2022 - entbjb.com
… pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the
head and neck (… methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck …
head and neck (… methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck …
免疫检查点抑制剂在复发或转移性头颈鳞癌的治疗进展
陈曦， 乔明哲 - 山东大学耳鼻喉眼学报, 2019 - ebhyxbwk.njournal.sdu.edu.cn
… with cetuximab is the standard treatment for recurrent or metastatic head and neck squamous
cell cancer(… Antitumor ac⁃ tivity of pembrolizumab in biomarker-unselected pa⁃ tients with …
cell cancer(… Antitumor ac⁃ tivity of pembrolizumab in biomarker-unselected pa⁃ tients with …
[PDF][PDF] 程序性死亡受体-1 及其配体抑制剂在头颈部鳞状细胞癌免疫治疗的研究进展
曾飞， 卢洁， 孙仁浩， 房义康， 禹雯怡， 杨芳… - 口腔疾病防治, 2021 - scholar.archive.org
… Platinum⁃based chemo⁃ therapy plus cetuximab in head and neck cancer[J]. … pembrolizumab
for treatment of recurrent or metastatic squa⁃ mous cell carcinoma of the head and neck (…
for treatment of recurrent or metastatic squa⁃ mous cell carcinoma of the head and neck (…
抗EGFR 单抗治疗复发/转移性头颈部鳞状细胞癌临床共识(2021 年版)
郭晔， 张陈平 - 中国癌症杂志, 2021 - china-oncology.com
… plus cetuximab in Chinese patients with recurrent and/or … evaluating pembrolizumab
combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous …
combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous …
[PDF][PDF] 2016 年头颈肿瘤研究进展
郑登云， 杨丽辉， 管吉林 - 循证医学, 2017 - jebm.cn
… Pembrolizumab 治疗头颈部鳞癌的Ⅰ期临床研究结 … Antitumor activity of Pembrolizumab in
biomarker unselected patients with recurrent and/or metastatic head and neck squamous cell …
biomarker unselected patients with recurrent and/or metastatic head and neck squamous cell …